LM-108

Phase 3Small molecule

LM-108 is one of 57 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Prolia

Amgen

Preclinical

14 2

LM-108

LLaNova Medicines Limited

Phase 3

1 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Bisphosphonate

Amgen

Preclinical

2 9

Tianeptine

Pfizer

Preclinical

1 10

Promestriene

UUniversity of Sao Paulo General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Breast Cancer

NCT06387628

Q3 2028

Phase 3Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

NCT07362186

Q4 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06821503

Q1 2030

Phase 2Not yet recruiting

Advanced Solid Tumours

NCT06873854

Clinical

Trials by Indication[1]

Advanced Solid Tumours3 trials

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Completed·LLaNova Australia Pty Limited·Phase 1/2·NCT05199753·78 enrolled

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated·LLaNova Medicines Limited·Phase 1/2·NCT05255484·24 enrolled

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Not yet recruiting·LLaNova Medicines Limited·Phase 2·NCT06873854·84 enrolled

Advanced Solid Tumors2 trials

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT06821503·72 enrolled

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Active, not recruiting·LLaNova Medicines Limited·Phase 1/2·NCT05518045·392 enrolled

Breast Cancer1 trial

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Recruiting·FFudan University·Phase 2·NCT06387628·74 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·LLaNova Medicines Limited·Phase 3·NCT07362186·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for LM-108. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LM-108 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LM-108. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaNova Medicines Limited

LM-108

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Q4 2028

Q1 2030

Trials by Indication[1]

Advanced Solid Tumours3 trials

Advanced Solid Tumors2 trials

Breast Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News